Depression is treated with psychotherapy, medication, or a combination of both, and most people see significant improvement with the right approach. About 50% to 55% of people reach remission after trying just two treatment steps, and that number climbs to roughly 81% after four sequential treatments, based on results from the landmark STAR*D trial, the largest real-world depression treatment study ever conducted.
Psychotherapy: What It Involves
Two forms of talk therapy have the strongest track records for depression. Cognitive behavioral therapy (CBT) works by helping you identify and change distorted thinking patterns that fuel depressive episodes. The core idea is that your interpretation of events, not the events themselves, drives your emotional response. A therapist helps you recognize those automatic negative thoughts and replace them with more accurate ones.
Interpersonal therapy (IPT) takes a different angle. Instead of targeting thought patterns, it focuses on improving the relationships and social interactions connected to your depressive symptoms. If a conflict with a partner, the loss of a loved one, or social isolation is feeding your depression, IPT addresses those issues directly.
Both therapies produce strong results. In one randomized controlled trial, about 76% of people in CBT and 79% in IPT met improvement criteria on a standard depression scale after completing treatment. The two approaches are roughly comparable in effectiveness, so the better fit often comes down to whether your depression is more closely tied to your thinking habits or your relationships.
Antidepressant Medication
SSRIs are the most commonly prescribed first-line medication. They work by increasing the availability of serotonin, a brain chemical involved in mood regulation. SNRIs do the same thing but also boost norepinephrine, which plays a role in stress response and alertness. Older classes like tricyclics and MAOIs affect a broader range of brain chemicals and are generally reserved for cases where newer options haven’t worked.
Antidepressants typically take one to two weeks before you notice any change, and they can require up to eight weeks to reach their full effect. This lag is one of the most frustrating parts of treatment. The initial remission rate with a first medication is about 28%. If that one doesn’t work, switching to a different drug or adding a second medication brings the cumulative remission rate to roughly 50% to 55%. Each subsequent step adds more people to the remission column, though the gains get smaller with each round: about 18% remit at step three and 10% at step four.
Around 20% of people who don’t respond in the first four weeks will respond during weeks five through eight, so sticking with a medication long enough to give it a fair trial matters before switching.
Side Effects of Antidepressants
Side effects are a major reason people stop taking their medication, and some are more common than clinical trials initially suggested. Sexual dysfunction is the most underreported: only 2% to 7% of patients mention it on their own, but when directly asked through questionnaires, 55% of people on SSRIs report some form of sexual side effect. That gap between reported and actual rates means it’s worth bringing up proactively with your prescriber.
Weight gain is another concern. Over six to twelve months of use, studies have documented average gains ranging from about 15 to 24 pounds depending on the specific SSRI. Some medications in this class are also more likely to cause anxiety, agitation, or insomnia, particularly in the early weeks. These side effects often improve with time or a dose adjustment, but if they don’t, switching to a different medication within the same class or to a different class entirely is a standard next step.
Combining Therapy and Medication
For many people, the most effective approach pairs medication with psychotherapy. Research on combined treatment shows that an SSRI plus CBT outperforms CBT alone. Interestingly, the combination doesn’t always clearly outperform medication alone in clinical trials, which suggests that medication carries significant weight in the equation. Still, therapy provides skills for managing future episodes and addressing the thought patterns or relationship problems that medication doesn’t touch.
The practical advantage of combination treatment is resilience. Medication can lift you out of the acute episode, while therapy gives you tools to recognize warning signs and interrupt the cycle if depression returns. Since depression has a high recurrence rate, that long-term skill-building matters.
Exercise as a Treatment Tool
Physical activity has a measurable antidepressant effect. Aerobic exercise (running, swimming, cycling) consistently outperforms no-treatment controls in reducing depressive symptoms. The effect size is modest but statistically significant, roughly comparable to the lower end of what you’d expect from medication in mild to moderate depression.
Resistance training shows less consistent results for depression specifically, though it does improve self-esteem, which is often eroded by depressive episodes. The most practical takeaway: regular aerobic exercise is a meaningful addition to other treatments, not a replacement for them in moderate or severe cases.
Treatment-Resistant Depression
If you’ve tried two or more antidepressants at adequate doses for adequate durations and haven’t improved, you meet the clinical definition of treatment-resistant depression (TRD). This isn’t rare. The standard approach at this point involves switching to a medication from a different class, or augmenting your current medication with a second one. Adding a medication that works through a different mechanism than your primary antidepressant often succeeds where simply increasing the dose does not.
Esketamine, a nasal spray derived from the anesthetic ketamine, was approved specifically for treatment-resistant depression. It’s administered in a certified medical setting because patients need monitoring afterward, and the treatment schedule starts at twice weekly before tapering to every one or two weeks during maintenance. It works through a completely different pathway than traditional antidepressants, targeting a receptor system involved in rapid mood shifts. For people who’ve struggled through multiple failed medication trials, it represents a meaningfully different biological approach rather than another variation on the same theme.
Brain Stimulation Therapies
When medication and therapy aren’t enough, brain stimulation offers another path. Electroconvulsive therapy (ECT) remains the most effective short-term treatment for severe depression, achieving a response rate of about 64% and remission in 53% of patients. It’s performed under general anesthesia and involves brief electrical stimulation that triggers a controlled seizure. The need for anesthesia and the stigma surrounding the procedure limit its use, but for severe or psychotic depression, its efficacy is unmatched.
Transcranial magnetic stimulation (TMS) is a less invasive alternative. It uses magnetic pulses delivered through a coil placed against the scalp, requires no anesthesia, and is done in an outpatient setting. Its response rate is lower than ECT’s (about 49% for high-frequency stimulation), but it’s better tolerated, with fewer side effects and lower dropout rates. For people who find ECT unacceptable or who have milder treatment resistance, TMS is a viable middle ground.
Newer Medications for Specific Populations
Zuranolone, approved in 2023, is the first oral medication specifically for postpartum depression. It works through a mechanism distinct from SSRIs, modulating a brain signaling system tied to hormonal shifts after childbirth. The treatment course is short: 14 days of a once-daily pill, with improvements showing up as early as day 15 in clinical trials. That rapid timeline is significant because postpartum depression disrupts bonding during a critical window, and traditional antidepressants can take two months to fully work. The main precaution is that it affects alertness, so driving and similar activities need to be limited during the treatment period.